In conclusion, the CD19-DEK variant was able to mediate ADCC and ADCP of B-ALL cell lines with different CD19 expression levels comparable to CD19-DE, which suggests that introduction of the E345K amino acid exchange has no significant negative impact on enhanced effector cell-mediated killing of antibodies carrying the ADCC and ADCP enhancing DE-mutations. Here, CD19 is linked to acute lymphoblastic leukemia.